• Home
  •  / Osiris Therapeutics
ProfileJobs

Osiris Therapeutics

Suggest Edit
Healthcarebiotechgenetics

Osiris Therapeutics is a company that researches, develops, manufactures, markets, and distributes regenerative medicine products. Its product Grafix is a cryopreserved placental membrane for treating acute and chronic wounds, venous leg ulcers, and burns. In addition, the company offers BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery, and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.

Revenue(FY, 2018)
$142.8 M

Employee Rating

2.4More
TypeSubsidiary
Parent CompanySmith & Nephew
HQColumbia, MD, US
Founded1992
Websiteosiris.com
Cybersecurity ratingFMore
Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, MD, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Osiris Therapeutics

Samson Tom

Samson Tom

President and CEO
Jason Keefer

Jason Keefer

Chief Commercial Officer
Alla Danilkovitch

Alla Danilkovitch

Chief Scientific Officer
Show more

Osiris Therapeutics Office Locations

Osiris Therapeutics has an office in Columbia
Columbia, MD, US (HQ)
7015 Albert Einstein Dr
Show all (1)

Osiris Therapeutics Financials and Metrics

Summary Metrics

Founding Date

1992

Total Funding

$65 m

Investors

Mesoblast
In total, Osiris Therapeutics had raised $65 m. Osiris Therapeutics is a subsidiary of Smith & Nephew

Osiris Therapeutics Revenue

Embed Graph
View revenue for all periods
Osiris Therapeutics's revenue was reported to be $142.82 m in FY, 2018
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2017FY, 2018

Revenue

41.1m7.8m24.3m59.9m118.5m142.8m

Cost of goods sold

531.0k2.6m6.7m13.2m32.7m38.1m

Gross profit

40.6m5.3m17.7m46.7m85.8m104.7m

Gross profit Margin, %

99%67%73%78%72%73%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Revenue

10.2m10.2m3.4m1.6m2.2m4.1m5.3m6.9m10.1m13.3m17.2m21.0m23.7m25.3m31.6m33.9m36.5m

Cost of goods sold

55.0k139.0k387.0k552.0k732.0k1.1m1.5m1.9m2.2m2.9m3.8m4.6m5.1m5.4m8.9m9.7m9.8m

Gross profit

10.2m10.1m3.1m1.1m1.4m2.9m3.8m5.0m7.8m10.4m13.4m16.4m18.5m19.9m22.8m24.2m26.7m

Gross profit Margin, %

99%99%89%66%66%72%72%73%78%78%78%78%78%79%72%71%73%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2017FY, 2018

Cash

1.7m1.9m2.4m2.2m3.1m16.4m

Accounts Receivable

728.0k3.1m7.5m24.3m26.1m22.5m

Prepaid Expenses

470.0k603.0k355.0k650.0k2.9m3.5m

Inventories

767.0k1.3m1.9m10.9m11.3m9.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Cash

1.5m1.4m1.6m1.1m1.1m1.3m1.6m1.8m2.3m2.7m946.0k3.7m1.6m15.8m3.4m23.1m31.7m

Accounts Receivable

1.6m1.5m997.0k1.4m2.2m5.3m6.4m6.8m11.8m16.9m21.4m32.0m38.6m37.9m26.5m23.5m20.6m

Prepaid Expenses

743.0k762.0k636.0k3.4m1.1m462.0k356.0k639.0k318.0k404.0k489.0k579.0k1.2m1.2m3.1m2.9m3.4m

Inventories

623.0k729.0k415.0k475.0k922.0k1.6m1.7m1.7m2.3m5.5m8.8m11.9m13.3m15.8m11.0m11.1m10.6m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2017FY, 2018

Net Income

14.9m(11.1m)8.8m36.9m

Depreciation and Amortization

745.0k708.0k587.0k940.0k688.0k873.0k

Inventories

(511.0k)(651.0k)(9.0m)88.0k135.0k

Accounts Payable

(912.0k)246.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Net Income

5.8m9.8m(1.3m)(5.5m)(8.5m)(2.7m)(6.5m)1.4m2.5m622.0k(2.3m)164.0k4.4m

Depreciation and Amortization

375.0k560.0k177.0k348.0k528.0k185.0k369.0k273.0k214.0k441.0k685.0k267.0k547.0k850.0k211.0k426.0k658.0k

Inventories

(333.0k)(418.0k)(394.0k)(408.0k)(3.6m)(6.9m)(1.0m)(2.4m)(4.7m)262.0k(616.0k)(536.0k)

Accounts Payable

(1.2m)21.0k101.0k449.0k267.0k(33.0k)
show all
USDQ2, 2011

Financial Leverage

1.8 x
Show all financial metrics

Osiris Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

F

58/100

Learn more about our premium products
SecurityScorecard logo

Osiris Therapeutics Online and Social Media Presence

Osiris Therapeutics's Trends

Embed Graph

Osiris Therapeutics Company Culture

  • CEO Rating

    F

    50/100

Learn more on Comparably

Osiris Therapeutics News and Updates

October 29, 2020

Stem Cell Manufacturing Market New Business Experts Ideas By Miltenyi Biotec, Pharmicell, Osiris Therapeutics,

Stem cell manufacturing discusses the required technologies that enable the transfer of the current laboratory-based practice of stem cell tissue culture to the clinic environment as therapeutics, while concurrently achieving control, reproducibility, automation, validation, and safety of the proces…
April 17, 2019

Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc

COLUMBIA, Md., April 17, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has completed the previously announced sale of Osiris t…
March 27, 2019

OSIRIS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc

NEW YORK, March 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Osiris Therapeutics, Inc. ("OSIRIS" or the "Company") (NASDAQ:OSIR) with Smith & Nephew plc. Click here for more information:...
March 15, 2019

SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.

NEW YORK, March 15, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Osiris Therapeutics, Inc. ("OSIR" or the "Company") (NASDAQ: OSIR) in connection with the proposed acquisition of the Company ...
March 13, 2019

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OSIR

NEW YORK, March 13, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NasdaqGM:...
March 12, 2019

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.

NEW YORK, March 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Osiris Therapeutics, Inc. (NASDAQ: OSIR) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Smith & Nephew plc. Stockholders will...
Show more

Osiris Therapeutics Blogs

March 12, 2019

Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.

LONDON , March 12, 2019 /PRNewswire/ --  Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company delivering regenerative medicine products, including skin, bone graft a…
November 07, 2018

OSIRIS THERAPEUTICS, INC REPORTS THIRD QUARTER 2018 RESULTS

The post OSIRIS THERAPEUTICS, INC REPORTS THIRD QUARTER 2018 RESULTS appeared first on Osiris Therapeutics, Inc..
September 11, 2018

Charles A. Rienhart, III

Charles A. Rienhart, III Kathy.Symes@na… Tue, 09/11/2018 - 17:12 Charles A. Rienhart, III Board Member Charles A. Reinhart, III was appointed to the Board in September 2018. Mr. Reinhart is currently the Chief Financial Officer at Pacira. He joined Pacira …
August 27, 2018

Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial

The post Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial appeared first on…
August 01, 2018

Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018

The post Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018 appeared first on Osiris Therapeutics, Inc..
July 11, 2018

Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers

The post Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers appeared first on Osiris Therapeutics, Inc..
Show more

 Osiris Therapeutics Frequently Asked Questions

  • When was Osiris Therapeutics founded?

    Osiris Therapeutics was founded in 1992.

  • Who are Osiris Therapeutics key executives?

    Osiris Therapeutics's key executives are Samson Tom, Jason Keefer and Alla Danilkovitch.

  • How many employees does Osiris Therapeutics have?

    Osiris Therapeutics has 256 employees.

  • What is Osiris Therapeutics revenue?

    Latest Osiris Therapeutics annual revenue is $142.8 m.

  • What is Osiris Therapeutics revenue per employee?

    Latest Osiris Therapeutics revenue per employee is $557.9 k.

  • Who are Osiris Therapeutics competitors?

    Competitors of Osiris Therapeutics include ACell, Touchlight Genetics and Personal Genome Diagnostics (PGD).

  • Where is Osiris Therapeutics headquarters?

    Osiris Therapeutics headquarters is located at 7015 Albert Einstein Dr, Columbia.

  • Where are Osiris Therapeutics offices?

    Osiris Therapeutics has an office in Columbia.

  • How many offices does Osiris Therapeutics have?

    Osiris Therapeutics has 1 office.